{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:37:03Z","timestamp":1790807823027,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Only limited information is available on the role of complement activation in malignant pleural mesothelioma (MPM). Thus, we investigated the circulating and tissue levels of the complement component 4d (C4d) in MPM. Plasma samples from 55 MPM patients, 21 healthy volunteers (HV) and 14 patients with non-malignant pleural diseases (NMPD) were measured by ELISA for C4d levels. Tissue specimens from 32 patients were analyzed by C4d immunohistochemistry. Tumor volumetry was measured in 20 patients. We found no C4d labeling on tumor cells, but on ectopic lymphoid structures within the tumor stroma. Plasma C4d levels did not significantly differ between MPM, HV or NMPD. Late-stage MPM patients had higher plasma C4d levels compared to early-stage (p\u2009=\u20090.079). High circulating C4d was associated with a higher tumor volume (p\u2009=\u20090.047). Plasma C4d levels following induction chemotherapy were significantly higher in patients with stable\/progressive disease compared to those with partial\/major response (p\u2009=\u20090.005). Strikingly, patients with low C4d levels at diagnosis had a significantly better overall survival, confirmed in a multivariate cox regression model (hazard ratio 0.263, p\u2009=\u20090.01). Our findings suggest that circulating plasma C4d is a promising new prognostic biomarker in patients with MPM and, moreover, helps to select patients for surgery following induction chemotherapy.<\/jats:p>","DOI":"10.1038\/s41598-017-16551-7","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T10:20:18Z","timestamp":1511346018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma"],"prefix":"10.1038","volume":"7","author":[{"given":"Thomas","family":"Klikovits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Laszlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Alireza","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahil","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frauenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Dan Linh","family":"Nguyen-Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Weder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9340","authenticated-orcid":false,"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-991X","authenticated-orcid":false,"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klepetko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"Renyi-Vamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-4153","authenticated-orcid":false,"given":"Balazs","family":"Hegedus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"16551_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000113629","volume":"75","author":"MA Jantz","year":"2008","unstructured":"Jantz, M. A. & Antony, V. B. Pathophysiology of the pleura. Respiration \n                           75, 121\u2013133 (2008).","journal-title":"Respiration"},{"key":"16551_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s004080000075","volume":"179","author":"JS Jones","year":"2001","unstructured":"Jones, J. S. The pleura in health and disease. Lung \n                           179, 397\u2013413 (2001).","journal-title":"Lung"},{"key":"16551_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(07)60412-7","volume":"369","author":"RT Lin","year":"2007","unstructured":"Lin, R. T. et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet \n                           369, 844\u2013849 (2007).","journal-title":"Lancet"},{"key":"16551_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson, B. W., Musk, A. W. & Lake, R. A. Malignant mesothelioma. Lancet \n                           366, 397\u2013408 (2005).","journal-title":"Lancet"},{"key":"16551_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol \n                           21, 2636\u20132644 (2003).","journal-title":"J Clin Oncol"},{"key":"16551_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/1541-7786.MCR-10-0225","volume":"8","author":"MJ Rutkowski","year":"2010","unstructured":"Rutkowski, M. J., Sughrue, M. E., Kane, A. J., Mills, S. A. & Parsa, A. T. Cancer and the complement cascade. Mol Cancer Res \n                           8, 1453\u20131465 (2010).","journal-title":"Mol Cancer Res"},{"key":"16551_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol \n                           11, 785\u2013797 (2010).","journal-title":"Nat Immunol"},{"key":"16551_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature \n                           420, 860\u2013867 (2002).","journal-title":"Nature"},{"key":"16551_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol \n                           3, 991\u2013998 (2002).","journal-title":"Nat Immunol"},{"key":"16551_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature \n                           454, 436\u2013444 (2008).","journal-title":"Nature"},{"key":"16551_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.it.2009.04.002","volume":"30","author":"MM Markiewski","year":"2009","unstructured":"Markiewski, M. M. & Lambris, J. D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol \n                           30, 286\u2013292 (2009).","journal-title":"Trends Immunol"},{"key":"16551_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/jnci\/djt205","volume":"105","author":"D Ajona","year":"2013","unstructured":"Ajona, D. et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst \n                           105, 1385\u20131393 (2013).","journal-title":"J Natl Cancer Inst"},{"key":"16551_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-565","volume":"12","author":"K Makela","year":"2012","unstructured":"Makela, K., Helen, P., Haapasalo, H. & Paavonen, T. Complement activation in astrocytomas: deposition of C4d and patient outcome. BMC Cancer \n                           12, 565 (2012).","journal-title":"BMC Cancer"},{"key":"16551_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1034\/j.1600-6143.2003.00171.x","volume":"3","author":"HE Feucht","year":"2003","unstructured":"Feucht, H. E. Complement C4d in graft capillaries\u2013the missing link in the recognition of humoral alloreactivity. Am J Transplant \n                           3, 646\u2013652 (2003).","journal-title":"Am J Transplant"},{"key":"16551_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.trre.2009.02.005","volume":"23","author":"K Murata","year":"2009","unstructured":"Murata, K. & Baldwin, W. M. 3rd Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) \n                           23, 139\u2013150 (2009).","journal-title":"Transplant Rev (Orlando)"},{"key":"16551_CR16","doi-asserted-by":"publisher","first-page":"e0119878","DOI":"10.1371\/journal.pone.0119878","volume":"10","author":"D Ajona","year":"2015","unstructured":"Ajona, D. et al. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PLoS One \n                           10, e0119878 (2015).","journal-title":"PLoS One"},{"key":"16551_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/odi.12363","volume":"21","author":"D Ajona","year":"2015","unstructured":"Ajona, D. et al. Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Dis \n                           21, 899\u2013904 (2015).","journal-title":"Oral Dis"},{"key":"16551_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1378\/chest.121.1.273","volume":"121","author":"V Galani","year":"2002","unstructured":"Galani, V. et al. Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of \u201cprotection\u201d against neoplasia? Chest \n                           121, 273\u2013278 (2002).","journal-title":"Chest"},{"key":"16551_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000195740","volume":"55","author":"LV Zerva","year":"1989","unstructured":"Zerva, L. V., Constantopoulos, S. H. & Moutsopoulos, H. M. Humoral immunity alterations after environmental asbestos exposure. Respiration \n                           55, 237\u2013241 (1989).","journal-title":"Respiration"},{"issue":"Pt 2","key":"16551_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/bj3260377","volume":"326","author":"K Nabil","year":"1997","unstructured":"Nabil, K. et al. Identification of human complement factor H as a chemotactic protein for monocytes. Biochem J \n                           326(Pt 2), 377\u2013383 (1997).","journal-title":"Biochem J"},{"key":"16551_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/09031936.00146110","volume":"38","author":"T Frauenfelder","year":"2011","unstructured":"Frauenfelder, T. et al. Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma? Eur Respir J \n                           38, 162\u2013168 (2011).","journal-title":"Eur Respir J"},{"key":"16551_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0169-5002(95)00508-0","volume":"14","author":"VW Rusch","year":"1996","unstructured":"Rusch, V. W. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer \n                           14, 1\u201312 (1996).","journal-title":"Lung Cancer"},{"key":"16551_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.prp.2006.11.004","volume":"203","author":"X Bu","year":"2007","unstructured":"Bu, X., Zheng, Z., Wang, C. & Yu, Y. Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells. Pathol Res Pract \n                           203, 163\u2013167 (2007).","journal-title":"Pathol Res Pract"},{"key":"16551_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/bjc.2013.815","volume":"110","author":"B Ghanim","year":"2014","unstructured":"Ghanim, B. et al. Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer \n                           110, 984\u2013990 (2014).","journal-title":"Br J Cancer"},{"key":"16551_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","volume":"256","author":"B Ghanim","year":"2012","unstructured":"Ghanim, B. et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg \n                           256, 357\u2013362 (2012).","journal-title":"Ann Surg"},{"key":"16551_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2016.04.018","volume":"63","author":"MA Hoda","year":"2016","unstructured":"Hoda, M. A. et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer \n                           63, 64\u201373 (2016).","journal-title":"Eur J Cancer"},{"key":"16551_CR27","first-page":"10633","volume":"8","author":"X Jing","year":"2015","unstructured":"Jing, X. et al. Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med \n                           8, 10633\u201310639 (2015).","journal-title":"Int J Clin Exp Med"},{"key":"16551_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3346\/jkms.2014.29.4.507","volume":"29","author":"KH Kim","year":"2014","unstructured":"Kim, K. H. et al. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci \n                           29, 507\u2013511 (2014).","journal-title":"J Korean Med Sci"},{"key":"16551_CR29","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1593\/neo.81582","volume":"11","author":"CW Seder","year":"2009","unstructured":"Seder, C. W. et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia \n                           11, 388\u2013396 (2009).","journal-title":"Neoplasia"},{"key":"16551_CR30","first-page":"12","volume":"2","author":"S Mohr","year":"2005","unstructured":"Mohr, S., Bottin, N. A., Micillino, M. C., Keith, J. C. & Rihn, G. B.H. Immune Signature of Malignant Pleural Mesothelioma as Assessed by Transcriptome Analysis. Cancer genomics proteomics \n                           2, 12 (2005).","journal-title":"Cancer genomics proteomics"},{"key":"16551_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semnephrol.2015.08.006","volume":"35","author":"DJ Birmingham","year":"2015","unstructured":"Birmingham, D. J. & Hebert, L. A. The Complement System in Lupus Nephritis. Semin Nephrol \n                           35, 444\u2013454 (2015).","journal-title":"Semin Nephrol"},{"key":"16551_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/imr.12462","volume":"274","author":"M Martin","year":"2016","unstructured":"Martin, M. & Blom, A. M. Complement in removal of the dead - balancing inflammation. Immunol Rev \n                           274, 218\u2013232 (2016).","journal-title":"Immunol Rev"},{"key":"16551_CR33","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1538-7836.2010.04172.x","volume":"9","author":"WS Speidl","year":"2011","unstructured":"Speidl, W. S., Kastl, S. P., Huber, K. & Wojta, J. Complement in atherosclerosis: friend or foe? J Thromb Haemost \n                           9, 428\u2013440 (2011).","journal-title":"J Thromb Haemost"},{"key":"16551_CR34","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","volume":"30","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet, K. et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol \n                           30, 1541\u20131549 (2012).","journal-title":"J Clin Oncol"},{"key":"16551_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/bjc.2015.286","volume":"113","author":"MB Kirschner","year":"2015","unstructured":"Kirschner, M. B. et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer \n                           113, 963\u2013969 (2015).","journal-title":"Br J Cancer"},{"key":"16551_CR36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BW Robinson","year":"2003","unstructured":"Robinson, B. W. et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet \n                           362, 1612\u20131616 (2003).","journal-title":"Lancet"},{"key":"16551_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol \n                           15, 257\u2013260 (2004).","journal-title":"Ann Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16551-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T14:13:28Z","timestamp":1671804808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16551"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-16551-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]},"assertion":[{"value":"18 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16456"}}